NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy

Next Previous
Trial Profile

NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs ALT 803 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Natural killer cell therapy (Primary) ; Avelumab; Bevacizumab; Brachyury peptide vaccine; Capecitabine; Cisplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Omega-3-acid ethyl esters; Paclitaxel
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NantCell

    • Most Recent Events

    • 26 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top